Top Institutional Investors

Affinity Asset Advisors, LLC — 13F Holdings & Portfolio

CIK 1773195 · latest 13F-HR filed 2026-08-13

Backtest portfolio

Affinity Asset Advisors, LLC manages $2.21B in 13F-reported U.S. long-equity assets across 113 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ROIV (6.00%), APGE (5.92%), SYRE (5.13%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 19 new positions and exited 10; 56 existing positions rose in reported value and 21 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$2.21B

Long-equity book

Holdings
113

Distinct positions

Period
2026-06-30

Filed 2026-08-13

Q/Q Activity
+19 / −10 / ↑56 / ↓21

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
ROIV6.5% · +34%APGE6.4% · -23%SYRE5.6% · 0%XENE4.7% · -5%ERAS4.7% · -2%INSM3.4% · +35%PRAX3.0% · +9%ALKS2.9% · -17%ORKA2.7% · +18%ANAB2.7% · -12%AVTX2.6% · +116%CYTK2.3% · -22%RVMD2.3% · +150%ABVX2.2% · -18%TRAX2.0% · newDNTH1.9% · +14%STRO1.9% · +10%NUVL1.7% · -8%TRVI1.6% · -10%OVID1.3% · -5%LXEO1.3% · +15%CLDX1.3% · +40%BLTE1.2% · +154%ELVN1.2% · -15%FBRX1.2% · +13%NRIX1.1% · 0%ANRO1.1% · +70%MDGL1.1% · -27%PTGX1.0% · 0%MLYS1.0% · 0%RLAY1.0% · +162%SGMT0.9% · +188%JBIO0.9% · +31%COGT0.9% · -40%TVTX0.8% · 0%CGEM0.8% · +12%SVRA0.8% · 0%IDYA0.7% · newCATX0.7% · +33%ODTX0.7% · newCOGT0.7% · +57%HLXC0.7% · 0%EQ0.6% · +234%ESTA0.6% · +48%CLYM0.6% · +39%TEVA0.6% · -73%MANE0.6% · +43%ARWR0.6% · -25%OMEROS CORP0.6% · 0%TSHA0.6% · +75%DMRA0.5% · -6%EPRX0.5% · +4%VERA0.5% · 0%PRQR0.5% · +126%NAMS0.5% · 0%KRRO0.5% · 0%AVR0.4% · 0%ZURA0.4% · -43%QURE0.4% · newASND0.4% · -68%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 42.6%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Jul 27, 2026.

Assets Under Management
$2.45B
Discretionary
$2.45B
Employees
10
Accounts
3
Address
450 PARK AVENUE
SUITE 1403
NEW YORK, NY 10022
Phone
(646) 481-3856
Website
Name Title / Status Ownership Type
CHO, MICHAEL ControlCO-FOUNDER, MANAGING PARTNER AND PORTFOLIO MANAGER | MANAGING MEMBER
since Jan 2017
50–75%Individual
CHU, JONATHAN, BO-SHING ControlCO-FOUNDER | MEMBER
since Jan 2017
10–25%Individual
HELLER, DANIEL, BARRYCHIEF INVESTMENT OFFICER | MEMBER
since Jan 2021
10–25%Individual
NOSKER, PATRICK, LEONARDDIRECTOR OF RESEARCH | MEMBER
since Jan 2021
10–25%Individual
WEINSTEIN, ANDREW, BLAKECHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER
since Mar 2025
Less than 5%Individual
Ownership & leadership changes · 2 filings with changes since Mar 9, 2021

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 27, 2026 filing
  • ChangedWEINSTEIN, ANDREW, BLAKE · title CONTROLLER AND CHIEF COMPLIANCE OFFICER → CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER
Mar 27, 2025 filing
  • AddedWEINSTEIN, ANDREW, BLAKE · CONTROLLER AND CHIEF COMPLIANCE OFFICER · Less than 5%
  • ChangedCHU, JONATHAN, BO-SHING · title CO-FOUNDER AND CHIEF COMPLIANCE OFFICER | MEMBER → CO-FOUNDER | MEMBER
Mar 9, 2021 filing (earliest on record)
  • ListedCHO, MICHAEL · CO-FOUNDER, MANAGING PARTNER AND PORTFOLIO MANAGER | MANAGING MEMBER · 50–75% · control person
  • ListedCHU, JONATHAN, BO-SHING · CO-FOUNDER AND CHIEF COMPLIANCE OFFICER | MEMBER · 10–25% · control person
  • ListedHELLER, DANIEL, BARRY · CHIEF INVESTMENT OFFICER | MEMBER · 10–25%
  • ListedNOSKER, PATRICK, LEONARD · DIRECTOR OF RESEARCH | MEMBER · 10–25%

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Affinity Asset Advisors, LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 ROIVANT SCIENCES LTD ROIV G76279101 $132.7M 6.00% 3,750,000 SH
2 APOGEE THERAPEUTICS INC APGE 03770N101 $131.0M 5.92% 987,000 SH
3 SPYRE THERAPEUTICS INC SYRE 00773J202 $113.6M 5.13% 1,279,134 SH
4 XENON PHARMACEUTICALS INC XENE 98420N105 $96.3M 4.35% 1,595,000 SH
5 ERASCA INC ERAS 29479A108 $96.2M 4.35% 5,250,000 SH
6 INSMED INC INSM 457669307 $69.3M 3.13% 650,000 SH
7 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $61.9M 2.80% 185,000 SH
8 ALKERMES PLC ALKS G01767105 $58.9M 2.66% 1,125,000 SH
9 ORUKA THERAPEUTICS INC ORKA 687604108 $56.2M 2.54% 590,000 SH
10 ANAPTYSBIO INC ANAB 032724106 $55.8M 2.52% 826,109 SH
11 AVALO THERAPEUTICS INC AVTX 05338F306 $53.6M 2.42% 2,900,000 SH
12 CYTOKINETICS INC CYTK 23282W605 $46.9M 2.12% 550,000 SH
13 REVOLUTION MEDICINES INC RVMD 76155X100 $46.8M 2.12% 250,000 SH
14 ABIVAX SA ABVX 00370M103 $44.0M 1.99% 330,000 SH
15 FIRST TRACKS BIOTHERAPEUTICS TRAX 337185102 $40.9M 1.85% 2,032,012 SH
16 DIANTHUS THERAPEUTICS INC DNTH 252828108 $39.0M 1.76% 400,000 SH
17 SUTRO BIOPHARMA INC STRO 869367201 $38.9M 1.76% 1,172,487 SH
18 MODERNA INC Put MRNA 60770K107 $35.0M 1.58% 500,000 SH
19 NUVALENT INC NUVL 670703107 $34.0M 1.54% 275,000 SH
20 TREVI THERAPEUTICS INC TRVI 89532M101 $33.6M 1.52% 1,800,172 SH
21 MODERNA INC Call MRNA 60770K107 $33.3M 1.50% 475,000 SH
22 ARK ETF TR Call ARKG 00214Q302 $31.5M 1.43% 750,000 SH
23 OVID THERAPEUTICS INC OVID 690469101 $27.3M 1.23% 10,144,562 SH
24 LEXEO THERAPEUTICS INC LXEO 52886X107 $27.0M 1.22% 5,807,611 SH
25 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $26.0M 1.18% 700,000 SH
26 BELITE BIO INC BLTE 07782B104 $25.4M 1.15% 165,000 SH
27 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $25.4M 1.15% 500,000 SH
28 FORTE BIOSCIENCES INC FBRX 34962G208 $24.3M 1.10% 1,145,391 SH
29 ELI LILLY & CO Call LLY 532457108 $24.0M 1.08% 20,000 SH
30 NURIX THERAPEUTICS INC NRIX 67080M103 $23.5M 1.06% 967,620 SH
31 ALTO NEUROSCIENCE INC ANRO 02157Q109 $22.4M 1.01% 850,000 SH
32 MADRIGAL PHARMACEUTICALS INC MDGL 558868105 $21.5M 0.97% 40,000 SH
33 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $21.1M 0.95% 172,125 SH
34 MINERALYS THERAPEUTICS INC MLYS 603170101 $20.2M 0.91% 750,000 SH
35 RELAY THERAPEUTICS INC RLAY 75943R102 $19.6M 0.89% 1,050,000 SH
36 SAGIMET BIOSCIENCES INC SGMT 786700104 $19.3M 0.87% 2,497,864 SH
37 JADE BIOSCIENCES INC JBIO 008064206 $18.7M 0.84% 840,350 SH
38 COGENT BIOSCIENCES INC COGT 19240Q201 $17.4M 0.79% 450,000 SH
39 TRAVERE THERAPEUTICS INC TVTX 89422G107 $17.0M 0.77% 300,000 SH
40 CULLINAN THERAPEUTICS INC CGEM 230031106 $15.9M 0.72% 875,760 SH
41 SAVARA INC SVRA 805111101 $15.5M 0.70% 2,512,153 SH
42 IDEAYA BIOSCIENCES INC IDYA 45166A102 $14.9M 0.67% 400,000 SH
43 PERSPECTIVE THERAPEUTICS INC CATX 46489V302 $14.4M 0.65% 4,214,582 SH
44 ODYSSEY THERAPEUTICS INC ODTX 67613T104 $14.3M 0.65% 766,346 SH
45 COGENT BIOSCIENCES INC COGT 19240QAA0 $13.7M 0.62% 11,000,000 PRN
46 OMEROS CORP Put OMER 682143102 $13.4M 0.61% 1,411,300 SH
47 HELIX ACQUISITION CORP III HLXC G4444S107 $13.3M 0.60% 1,250,000 SH
48 EQUILLIUM INC EQ 29446K106 $13.1M 0.59% 4,100,000 SH
49 ALKERMES PLC Call ALKS G01767105 $13.1M 0.59% 250,000 SH
50 ESTABLISHMENT LABS HLDGS INC ESTA G31249108 $12.7M 0.57% 148,013 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-13 $2.21B 113 0001011438-26-000516
2026-03-31 2026-05-14 $1.94B 105 0001315863-26-000411
2025-12-31 2026-02-13 $1.76B 95 0001315863-26-000153
2025-09-30 2025-11-13 $1.15B 96 0001999371-25-017685
Filer Information
Address
450 PARK AVENUE
SUITE 1403
NEW YORK, NY 10022
Phone
(917) 826-4533
Filing Manager
Affinity Asset Advisors, LLC
NEW YORK, NY
Signatory
Andrew Weinstein
Chief Financial Officer and Chief Compliance Officer